Search
cenicriviroc
Indications:
- investigational drug candidate for
- treatment of HIV1 infection
- in combination with Tropifexor for non-alcoholic steatohepatitis
Contraindications:
- does not reduce recovery time in hospitalized patients with Covid-19 pneumonia [1]
- may have small mortality benefit
- all-cause 28-day mortality
- 13.8% for cenicriviroc vs 11.9% for placebo [1]
Dosage:
- loading dose 300 mg PO
- 150 mg PO BID
Mechanism of action:
- orally active dual inhibitor of CC chemokine receptor 2 (CCR2) & CCR5
- cenicriviroc inhibits HIV-1 & HIV-2
- potent anti-inflammatory & antiinfective activity [3]
General
receptor antagonist
antiviral agent
gastrointestinal agent
heterocyclic compound, 2 rings
aromatic compound
References
- O'Halloran JA, Ko ER, Anstrom KJ et al
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized
With COVID-19 Pneumonia. A Randomized Clinical Trial.
JAMA. 2023;330(4):328-339.
PMID: 37428480 PMCID: PMC10334296 (available on 2024-01-10)
https://jamanetwork.com/journals/jama/fullarticle/2807333
- DrugBank Online: Cenicriviroc
https://go.drugbank.com/drugs/DB11758
- Selleckchem: Cenicriviroc (TAK-652)
https://www.selleckchem.com/products/cenicriviroc.html